Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, today announced that it has entered into a definitive agreement to acquire Onspira Therapeutics, a private drug development company similarly focused on therapeutics for rare pulmonary diseases. This acquisition expands Altavant’s pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with orphan drug designation from the U.S. Food and Drug Administration. OSP-101 is in preclinical development for the treatment of bronchiolitis obliterans syndrome (BOS), the leading non-infectious complication following lung transplantation and a major cause of death in these patients.
Read the full article: Altavant Sciences Acquires Onspira Therapeutics //
Source: https://www.prnewswire.com/news-releases/altavant-sciences-acquires-onspira-therapeutics-adding-a-potentially-life-saving-treatment-for-post-lung-transplant-patients-to-the-altavant-pipeline-300983426.html